Deep Origin

How much of your pipeline still feels like a gamble? With a 30.6% hit rate across 80 billion compounds and binding poses predicted to 1.2Å before a crystal structure exists, your decisions start looking a lot less like bets and a lot more like strategy. Outperforming AlphaFold3, Boltz-1, and Chai-1 on novel targets means you can walk into your next meeting knowing your discovery engine isn’t guessing—it’s working.

Remember the first time you saw data that made you feel, “This could actually change everything”? That’s the moment you get when 30.6% of 80 billion compounds hit, and binding poses land within 1.2Å before a crystal structure even exists. You’re not just screening; you’re watching your odds of finding the right molecule transform from a grind into a genuine shot at the breakthrough you’ve been chasing—faster than AlphaFold3, Boltz-1, or Chai-1 on novel targets.

A 30.6% hit rate across 80B compounds. Binding poses predicted to 1.2Å before the crystal structure existed. Outperforming AlphaFold3, Boltz-1 and Chai-1 on novel targets.

Multiple validated - structurally distinct hits against a novel target - in under three months. BioAge Labs (Nasdaq: BIOA) put our screening to the test.

Backed with $31.7M to predict drug safety in silico — and cut the industry's reliance on animal testing.